<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00528424</url>
  </required_header>
  <id_info>
    <org_study_id>AUX-CC-858</org_study_id>
    <nct_id>NCT00528424</nct_id>
  </id_info>
  <brief_title>AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease</brief_title>
  <official_title>A Phase 3, Open-Label Extension Study of the Safety and Efficacy of AA4500 in the Treatment of Subjects With Advanced Dupuytren's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study AUX-CC-858 was an open-label continuation of the double-blind Study AUX-CC-857
      (NCT00528606). Subjects who complete the Day 90 visit after their initial injection in Study
      AUX-CC-857 (NCT00528606) entered into Study AUX-CC-858. Subjects who required further
      treatment in Study AUX-CC-858, either because their treated metacarpophalangeal and/or
      proximal interphalangeal (PIP) joints did not have a reduction in contracture to 5° or less,
      the cord affecting that joint received less than three injections of AA4500, or they had
      other eligible cords that received no treatment in AUX-CC-857 (NCT00528606), had the option
      to receive up to five injections of AA4500 in this extension study. Subjects requiring
      further treatment were followed for efficacy and safety on Days 1, 7, and 30 after each
      injection, with injections separated by four weeks. Follow-up visits for the determination of
      efficacy and safety were conducted on Day 90, Month 6, and Month 9.

      This study was designed to be part of the larger clinical program, for adult patients with
      Dupuytren's contracture with a palpable cord, where the data from 2 pivotal
      Placebo-Controlled studies (AUX-CC-857 (NCT00528606) and AUX-CC-859 (NCT00533273)) and 7
      non-pivotal studies were evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Contracture to 5° or Less</measure>
    <time_frame>Within 30 days after last injection</time_frame>
    <description>Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement After the Last Injection</measure>
    <time_frame>Baseline, within 30 days after last injection</time_frame>
    <description>Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction From Baseline Contracture After the Last Injection</measure>
    <time_frame>Baseline, Day 30 after last injection</time_frame>
    <description>Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Range of Motion After the Last Injection</measure>
    <time_frame>Baseline, Day 30 after last injection</time_frame>
    <description>Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion − baseline range of motion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Clinical Success</measure>
    <time_frame>Within 30 days after last injection</time_frame>
    <description>Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success After the First Injection</measure>
    <time_frame>Within 30 days after first injection</time_frame>
    <description>Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement After the First Injection</measure>
    <time_frame>Baseline, within 30 days after first injection</time_frame>
    <description>Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction From Baseline Contracture After the First Injection</measure>
    <time_frame>Baseline, Day 30 after first injection</time_frame>
    <description>Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Range of Motion After the First Injection</measure>
    <time_frame>Baseline, Day 30 after first injection</time_frame>
    <description>Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion − baseline range of motion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">286</enrollment>
  <condition>Advanced Dupuytren's Disease</condition>
  <arm_group>
    <arm_group_label>AA4500 0.58 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AA4500</intervention_name>
    <description>Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.</description>
    <arm_group_label>AA4500 0.58 mg</arm_group_label>
    <other_name>XIAFLEX®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion
             deformity of at least one finger, other than the thumb, that had a contracture at
             least 20°, but not greater than 100° for MP (80° for PIP) joints, caused by a palpable
             cord.

          -  Had a positive &quot;table top test,&quot; defined as the inability to simultaneously place the
             affected finger(s) and palm flat against a table top.

          -  Were naïve to AA4500 treatment or had received only one or two injections of AA4500
             for the treatment of advanced Dupuytren's disease in AUX-CC-857 ((NCT00528606).

          -  Were judged to be in good health.

          -  Must have participated in protocol AUX-CC-857 (NCT00528606).

        Exclusion Criteria:

          -  Had a chronic muscular, neurological, or neuromuscular disorder that affected the
             hands.

          -  Had received treatment for advanced Dupuytren's disease within 90 days of enrollment
             on the joint selected for the initial injection of AA4500, including surgery
             (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of
             verapamil and/or interferon.

          -  Had a known recent history of stroke, bleeding, a disease process that affected the
             hands, or other medical condition, which in the investigator's opinion, would make the
             subject unsuitable for enrollment in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Urdaneta, MD</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>100 UCLA Medical Plaza, Suite 305</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hand Surgery Clinic</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hand Surgery Associates, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hand and Upper Extremity Center of Georgia, P.C.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockford Orthopedic Associates, Ltd.</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Hand Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital, Department of Orthopedic Surgery</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newton-Wellesley Hospital</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRIA Orthopaedic Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Stony Brook - Department of Orthopedics</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hand Microsurgery &amp; Reconstructive Orthopaedics</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopaedics, Brown University, Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/downloads/Drugs/DrugSafety/UCM200615.pdf</url>
    <description>XIAFLEX Medication Guide</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125338lbl.pdf</url>
    <description>XIAFLEX Prescribing Information</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2007</study_first_submitted>
  <study_first_submitted_qc>September 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2007</study_first_posted>
  <results_first_submitted>September 24, 2010</results_first_submitted>
  <results_first_submitted_qc>September 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2010</results_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dupuytren Contracture</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AA4500 0.58 mg</title>
          <description>Collagenase clostridium histolyticum 0.58 mg injected into metacarpophalangeal (MP) and/or proximal interphalangeal (PIP) joints</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AA4500 0.58 mg</title>
          <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="286"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.7" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reduction in Contracture to 5° or Less</title>
        <description>Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
        <time_frame>Within 30 days after last injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in Contracture to 5° or Less</title>
          <description>Successfully treated or clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Percentage of joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement After the Last Injection</title>
        <description>Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
        <time_frame>Baseline, within 30 days after last injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement After the Last Injection</title>
          <description>Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Percentage of joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction From Baseline Contracture After the Last Injection</title>
        <description>Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture.</description>
        <time_frame>Baseline, Day 30 after last injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction From Baseline Contracture After the Last Injection</title>
          <description>Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture.</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.8" spread="39.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Range of Motion After the Last Injection</title>
        <description>Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion − baseline range of motion</description>
        <time_frame>Baseline, Day 30 after last injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Range of Motion After the Last Injection</title>
          <description>Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion − baseline range of motion</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="20.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach Clinical Success</title>
        <description>Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
        <time_frame>Within 30 days after last injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach Clinical Success</title>
          <description>Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection, displayed in post injection time point categories</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection 1, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 1, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 2, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection 3, Day 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did not reach Clinical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success After the First Injection</title>
        <description>Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
        <time_frame>Within 30 days after first injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success After the First Injection</title>
          <description>Clinical success in non-primary joints defined as reduction in contracture to within 0-5° of normal within 30 days of injection.</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Improvement After the First Injection</title>
        <description>Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
        <time_frame>Baseline, within 30 days after first injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Improvement After the First Injection</title>
          <description>Clinical improvement in non-primary joints defined as ≥50% reduction from baseline in the degree of contracture within 30 days after injection</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Percentage of Joints</units>
          <param>Number</param>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction From Baseline Contracture After the First Injection</title>
        <description>Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture.</description>
        <time_frame>Baseline, Day 30 after first injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction From Baseline Contracture After the First Injection</title>
          <description>Percent change in degree of contracture in non-primary joints measured as 100 * (baseline contracture − last available post-injection contracture)/baseline contracture.</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9" spread="38.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Range of Motion After the First Injection</title>
        <description>Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion − baseline range of motion</description>
        <time_frame>Baseline, Day 30 after first injection</time_frame>
        <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>AA4500 0.58 mg</title>
            <description>Collagenase clostridium histolyticum 0.58 mg injected into MP and/or PIP joints</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Range of Motion After the First Injection</title>
          <description>Change in degree of range of motion in non-primary joints measured as last available post-injection range of motion − baseline range of motion</description>
          <population>Evaluable non-primary joints treated with AA4500 with baseline fixed flexion contracture &gt;5° and at least 1 post-injection contracture measurement. For the purpose of analysis, 13 subjects with non-primary joints treated with AA4500 in double-blind study AUX-CC-857 are included in overall number of participants.</population>
          <units>Degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Joints</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Joints</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="19.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of study drug administration until 30 days after completion of or discharge from the study</time_frame>
      <desc>This study was designed to be part of the larger clinical program. For information regarding XIAFLEX-associated Serious and Non-serious Adverse events please refer to the XIAFLEX Medication Guide &amp; XIAFLEX Prescribing Information (see links above)</desc>
      <group_list>
        <group group_id="E1">
          <title>AA4500 0.58 mg</title>
          <description>collagenase clostridium histolyticum 0.58mg injected into metacarpophalangeal (MP) and/or proximal interphalangeal (PIP) joints</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Finger deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.0</frequency_threshold>
        <default_vocab>MedDRA (8.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="171" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="95" subjects_affected="52" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="74" subjects_affected="47" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="26" subjects_affected="15" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="56" subjects_affected="34" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="386" subjects_affected="136" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="15" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="75" subjects_affected="43" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="205" subjects_affected="95" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="98" subjects_affected="66" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="67" subjects_affected="39" subjects_at_risk="286"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="51" subjects_affected="33" subjects_at_risk="286"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Auxilium Pharmaceuticals, Inc. agreements may vary with individual investigators but will not prohibit any investigator from publishing. Auxilium supports the publication of results from all centers of a multicenter trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Coordinator</name_or_title>
      <organization>Endo Pharmaceuticals Inc.</organization>
      <email>clinicalsite.inquiries@endo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

